Lentiviral vector-based Japanese encephalitis immunogenic composition

Patent metadata

Field	Value
Publication number	US-10603374-B2
Application number	US-201515531157-A
Country	US
Kind code	B2
Filing date	Dec 7, 2015
Priority date	Dec 11, 2014
Publication date	Mar 31, 2020
Grant date	Mar 31, 2020

Abstract

The present invention relates to a lentiviral vector-based Japanese encephalitis (JE) immunogenic composition. The present invention is directed to a recombinant lentiviral vector expressing the precursor of membrane (prM) and the envelope (E) protein, in particular glycoprotein of a Japanese encephalitis virus (JEV) or immunogenic fragments thereof. The present invention also provides cells expressing the lentiviral vector, uses and methods to prevent a JEV infection in a mammalian host, especially in a human or an animal host, in particular a pig or a piglet, preferably a domestic pig or a domestic piglet.

First claim

The invention claimed is:

1. A recombinant lentiviral vector genome comprising lentiviral cis-active elements including long terminal repeats (LTRs) or modified LTRs including partially deleted 3′LTR, psi (Ψ) packaging signal, Rev responsive element (RRE) and DNA flap central polypurine tract (cPPT)/ central termination sequence (CTS), together with a transcription unit encoding the precursor of membrane (prM) and the envelope (E) protein of a Japanese encephalitis virus (JEV), wherein the E protein is either the full-length E protein or its soluble form lacking the two C-terminal transmembrane domains of the full-length E protein, and wherein the polynucleotide encoding the prM protein has the sequence of SEQ ID NO: 5, the polynucleotide encoding the full-length E protein has the sequence of SEQ ID NO: 8 and the polynucleotide encoding the soluble form of the E protein has the sequence of SEQ ID NO: 11.

2. The recombinant lentiviral vector genome according to claim 1 , wherein in the lentiviral 3′-LTR the promoter and the activator of the U3 region have been deleted, and wherein the polynucleotide encoding the prM and E proteins is placed under the control of a heterologous promoter.

3. The recombinant lentiviral vector genome according to claim 1 , wherein the lentiviral vector genome is derived from the genome of HIV.

4. The recombinant lentiviral vector genome according to claim 1 , wherein the lentiviral vector genome is derived from the genome of FIV.

5. The recombinant lentiviral vector genome according to claim 1 , which is replication-incompetent as a result of deletion of all or part of the gag and pol genes of the lentiviral genome or mutation in the gag and pol genes of the lentiviral genome, so that the gag and pol genes are not capable of encoding functional GAG and POL proteins.

6. A recombinant lentiviral vector, which is pTRIPΔU3.CMV/JEV.prME vector whose nucleic acid sequence is as defined in SEQ ID NO: 34, or pTRIPΔU3.CMV/JEV.prME ΔTM vector whose nucleic acid sequence is as defined in SEQ ID NO: 35.

7. A DNA plasmid comprising the recombinant lentiviral vector genome according to claim 1 .

8. An isolated host cell either transfected or genetically transformed with a DNA plasmid according to claim 7 .

9. Recombinant lentiviral vector particles expressing the recombinant lentiviral vector genome according to claim 1 , which are pseudotyped with a vesicular stomatitis virus glycoprotein G (VSV-G) protein.

10. An immunogenic composition comprising recombinant lentiviral vector particles according to claim 9 , in a dose sufficient to elicit an immune antibody response in a mammalian host.

11. The immunogenic composition according to claim 10 , which is in freeze-dried form, the freeze-drying being carried out in the presence of cryoprotective compounds.

12. The immunogenic composition according to claim 10 , wherein said composition is formulated for parenteral administration.

13. The immunogenic composition according to claim 10 , wherein said composition is formulated for administration in one or multiple administration dose(s).

14. A method to produce recombinant lentiviral vector particles suitable for the preparation of a JEV immunogenic composition, comprising or consisting of:
a) transfecting the recombinant lentiviral transfer vector carrying the lentiviral vector genome according to claim 1 , in a host cell;
b) co-transfecting the cell of step a) with a plasmid vector encoding the envelope protein VSG, and with a plasmid vector encoding the lentiviral GAG and POL or mutated POL protein as packaging construct;
c) recovering the recombinant lentiviral particles expressing JEV antigens.

15. The recombinant lentiviral vector genome according to claim 2 , wherein the heterologous promoter is the cytomegalovirus immediate early (CMVie) promoter.

16. The recombinant lentiviral vector genome according to claim 3 , wherein the genome of HIV is of HIV-1.

17. The immunogenic composition according to claim 11 , wherein the cryoprotective compounds are trehalose.

18. The immunogenic composition according to claim 12 , wherein the parenteral administration is subcutaneous (s.c), intradermal (i.d.), intramuscular (i.m.), intraperitoneal (i.p.) or intravenous (i.v.) injection.

19. The immunogenic composition according to claim 13 , wherein said composition is formulated in a prime-boost administration regime.

Assignees

• Pasteur Institut
• Centre Nat Rech Scient

Inventors

• Charneau Pierre
• Despres Philippe
• De Wispelaere Melissanne
• Souque Philippe
• Frenkiel Marie-Pascale

Classifications

• C07K2319/40

  containing a tag for immunodetection, or an epitope for immunisation · CPC title

• A61K47/26

  Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin · CPC title

• C12N2740/15043

  viral genome or elements thereof as genetic vector · CPC title

• C12N2770/24171

  Demonstrated in vivo effect · CPC title

• C12N15/86 Primary

  Viral vectors · CPC title